KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nu Skin Enterprises (NUS) Gains from Sales and Divestitures (2016 - 2025)

Nu Skin Enterprises' Gains from Sales and Divestitures history spans 14 years, with the latest figure at $48200.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 87.5% year-over-year to $48200.0; the TTM value through Dec 2025 reached $48200.0, down 87.5%, while the annual FY2025 figure was $48200.0, 87.5% down from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $48200.0 at Nu Skin Enterprises, down from $385700.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $385700.0 in Q4 2024 and bottomed at $48200.0 in Q4 2025.
  • The 4-year median for Gains from Sales and Divestitures is $317100.0 (2021), against an average of $267025.0.
  • The largest annual shift saw Gains from Sales and Divestitures skyrocketed 39.75% in 2021 before it tumbled 87.5% in 2025.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $307600.0 in 2021, then rose by 6.18% to $326600.0 in 2022, then grew by 18.1% to $385700.0 in 2024, then crashed by 87.5% to $48200.0 in 2025.
  • Per Business Quant, the three most recent readings for NUS's Gains from Sales and Divestitures are $48200.0 (Q4 2025), $385700.0 (Q4 2024), and $326600.0 (Q4 2022).